Literature DB >> 11297226

Allergic bronchopulmonary aspergillosis in Italian cystic fibrosis patients: prevalence and percentage of positive tests in the employed diagnostic criteria.

G Taccetti1, E Procopio, L Marianelli, S Campana.   

Abstract

The prevalence of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF) patients is difficult to determine because the data in the literature are not homogeneous or comparable. ABPA and CF have similar clinical symptoms which make diagnosis difficult and underestimate the real dimensions of the problem. We conducted an epidemiological study on 3089 Italian CF patients to determine the prevalence of ABPA in Italy and verify the percentage of positive tests in the employed diagnostic criteria. Our results indicate that the prevalence of ABPA in Italian CF patients is 6.18%, mainly in adolescents and young adults. ABPA is diagnosed using clinical symptoms (presence of episodic bronchial obstructions or typical radiographic features) and on the basis of other criteria which can only be partially fulfilled in paediatric patients. Among the diagnostic tests the most sensitive are the total IgE (84.5%), specific IgE anti-Aspergillus fumigatus (81.6%) and the prick test (68.3%). In the absence of clinical symptoms and gold standard diagnostic tests, serological positivity and/or the skin test are not sufficient evidence to confirm the presence of ABPA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11297226     DOI: 10.1023/a:1007670717619

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  20 in total

1.  Allergic bronchopulmonary aspergillosis and cystic fibrosis.

Authors:  C E Milla
Journal:  Pediatr Pulmonol       Date:  1999-02

2.  A 12-year longitudinal study of Aspergillus sensitivity in patients with cystic fibrosis.

Authors:  P S Hutcheson; A P Knutsen; A J Rejent; R G Slavin
Journal:  Chest       Date:  1996-08       Impact factor: 9.410

3.  Microbiologic data overview of Italian cystic fibrosis patients.

Authors:  G Taccetti; S Campana
Journal:  Eur J Epidemiol       Date:  1997-04       Impact factor: 8.082

4.  ABPA in CF: a devastating combination.

Authors:  R G Slavin
Journal:  Pediatr Pulmonol       Date:  1996-01

5.  Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis.

Authors:  M Rosenberg; R Patterson; R Mintzer; B J Cooper; M Roberts; K E Harris
Journal:  Ann Intern Med       Date:  1977-04       Impact factor: 25.391

6.  Prevalence of allergic bronchopulmonary aspergillosis and atopy in adult patients with cystic fibrosis.

Authors:  J W Becker; W Burke; G McDonald; P A Greenberger; W R Henderson; M L Aitken
Journal:  Chest       Date:  1996-06       Impact factor: 9.410

Review 7.  Immunologic aspects of lung diseases and cystic fibrosis.

Authors:  P A Greenberger
Journal:  JAMA       Date:  1997-12-10       Impact factor: 56.272

8.  Serum IgE and IgG antibody activity against Aspergillus fumigatus as a diagnostic aid in allergic bronchopulmonary aspergillosis.

Authors:  J L Wang; R Patterson; M Rosenberg; M Roberts; B J Cooper
Journal:  Am Rev Respir Dis       Date:  1978-05

9.  Non-aspergillus allergic bronchopulmonary mycosis in a pediatric patient with cystic fibrosis.

Authors:  M Gondor; M G Michaels; J D Finder
Journal:  Pediatrics       Date:  1998-12       Impact factor: 7.124

10.  Identification of allergic bronchopulmonary aspergillosis in cystic fibrosis patients by recombinant Aspergillus fumigatus I/a-specific serology.

Authors:  W H Nikolaizik; M Moser; R Crameri; S Little; J O Warner; K Blaser; M H Schöni
Journal:  Am J Respir Crit Care Med       Date:  1995-08       Impact factor: 21.405

View more
  3 in total

Review 1.  Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.

Authors:  Kana R Jat; Dinesh K Walia; Anju Khairwa
Journal:  Cochrane Database Syst Rev       Date:  2021-09-22

Review 2.  Allergic bronchopulmonary aspergillosis.

Authors:  Richard B Moss
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

Review 3.  Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.

Authors:  Kana R Jat; Dinesh K Walia; Anju Khairwa
Journal:  Cochrane Database Syst Rev       Date:  2018-03-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.